After several cycles of lab testing on test animals, a medication can enter clinical trials for evaluation in humans. In phase III clinical trial testing:
A) the trial is expanded to include a large sample size, usually in the thousands of individuals, and establish the overall safety and effectiveness of the drug.
B) the medication is compared to other medications on the market.
C) consists of the drug being tested on a small number (usually 300 or less) of people with the illness or condition the drug is designed to treat.
D) researchers attempt to determine the safe dose and how the medication is both absorbed and eliminated from the body.
Answer: A
You might also like to view...
A rhythm strip will be run in ________ for 20 seconds on the physician's request or, in some instances, if the medical assistant sees anything that appears abnormal on the tracing
a. lead I b. lead II c. lead III d. lead IV
Which statement is NOT true about disclosing agents, or disclosants?
A) They may be in either a liquid or a tablet form. B) They allow the patient to see plaque in the mouth before or after brushing. C) These agents can give patients a literal road map to remove the plaque. D) The chewable tablet or the liquid disclosant chewed and swallowed.